Profile data is unavailable for this security.
About the company
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-88.12m
- Incorporated2011
- Employees11.00
- LocationRenovaro IncCentury City Medical Plaza2080 Century City East, Suite 906LOS ANGELES 90067United StatesUSA
- Phone+1 (212) 763-0184
- Fax+1 (845) 818-3588
- Websitehttps://renovarobio.com/
More ▼
Mergers & acquisitions
| Acquired company | RENB:NAQ since announced | Transaction value |
|---|---|---|
| Gedi Cube Bv | -84.52% | -- |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDxHealth SA | 80.74m | -40.80m | 72.04m | 300.00 | -- | -- | -- | 0.8922 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Gritstone bio Inc | 14.61m | -133.03m | 74.14m | 231.00 | -- | 3.33 | -- | 5.07 | -1.35 | -1.35 | 0.1391 | 0.1884 | 0.08 | -- | 49.20 | 63,251.08 | -72.86 | -48.08 | -83.37 | -55.18 | -- | -- | -910.50 | -573.71 | -- | -97.11 | 0.6461 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| IO Biotech Inc | 0.00 | -88.00m | 74.45m | 68.00 | -- | 0.7733 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Omega Therapeutics Inc | 6.31m | -78.90m | 75.56m | 93.00 | -- | 2.88 | -- | 11.97 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Genelux Corp | 8.00k | -26.54m | 76.67m | 23.00 | -- | 2.01 | -- | 9,583.59 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Renovaro Inc | 0.00 | -88.12m | 76.70m | 11.00 | -- | 0.4549 | -- | -- | -1.08 | -1.08 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -60.56 | -27.81 | -68.21 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -48.88m | 77.28m | 63.00 | -- | 0.3606 | -- | -- | -0.9662 | -0.9662 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -20.38 | -21.16 | -21.39 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -34.44m | 77.84m | 16.00 | -- | 23.99 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | 57.92m | 78.50m | 17.00 | 1.22 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
| Cidara Therapeutics Inc | 31.58m | -116.17m | 79.32m | 69.00 | -- | 0.3933 | -- | 2.51 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 79.34m | 127.00 | -- | 1.49 | -- | 15.87 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
| Chimerix Inc | 144.00k | -84.70m | 79.76m | 72.00 | -- | 0.5126 | -- | 553.89 | -0.9507 | -0.9507 | 0.0016 | 1.74 | 0.0007 | -- | 1.86 | 2,000.00 | -40.37 | -30.45 | -44.33 | -34.09 | 10.42 | -- | -58,820.14 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 79.87m | 2.00 | -- | 16.02 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Aileron Therapeutics Inc | 0.00 | -25.22m | 80.81m | 15.00 | -- | 1.44 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Renovaro Inc's reporting currency: US Dollar USD
8.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 5.57m | 3.78% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.39m | 2.30% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.73m | 1.17% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.28m | 0.87% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 399.97k | 0.27% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 294.60k | 0.20% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 198.97k | 0.14% |
| BlackRock Investment Management LLCas of 30 Jun 2024 | 131.84k | 0.09% |
| The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 2024 | 107.15k | 0.07% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 103.17k | 0.07% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
